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ABSTRACT
Genomic variations deep in the intronic regions of
pre-mRNA molecules are increasingly reported to
affect splicing events. However, there is no general
explanation why apparently similar variations may
have either no effect on splicing or cause significant
splicing alterations. In this work we have examined
the structural architecture of pseudoexons pre-
viously described in ATM and CFTR patients. The
ATM case derives from the deletion of a repressor
element and is characterized by an aberrant 50ss
selection despite the presence of better alterna-
tives. The CFTR pseudoexon instead derives from
the creation of a new 50ss that is used while a nearby
pre-existing donor-like sequence is never selected.
Our results indicate that RNA structure is a major
splicing regulatory factor in both cases. Further-
more, manipulation of the original RNA structures
can lead to pseudoexon inclusion following the
exposure of unused 50ss already present in their
wild-type intronic sequences and prevented to be
recognized because of their location in RNA stem
structures. Our data show that intrinsic structural
features of introns must be taken into account to
understand the mechanism of pseudoexon activa-
tion in genetic diseases. Our observations may help
to improve diagnostics prediction programmes and
eventual therapeutic targeting.
INTRODUCTION
RNA secondary structure is increasingly recognized as a
powerful modiﬁer of splicing events (1). At the local level,
RNA conformations have been shown to regulate the
splicing process by aﬀecting the basic identifying features
of an exon. Numerous examples of such a regulatory role
have been recently reported to occur for the donor site of
Tau exon 10 (2), SMN2 exon 7 (3), the branch/acceptor
sites in Drosophila Adh gene (4), the internal splicing
enhancer region in the ﬁbronectin gene (5) or to silencer
regions in the presenilin 2 gene (6). In addition, RNA
secondary structures have been shown to involve interac-
tions between very distant regions of the pre-mRNA such
as in Saccharomyces cerevisiae (7,8), humans (9–11) and
Drosophila (12–14). Recently, complementary intron
sequence motifs have also been proposed to mediate the
peculiar phenomenon of exon repetition (15). Finally,
RNA secondary structures are increasingly shown to play
a part in other facets of mRNA biology such as in
mantaining its stability (16), regulating translation (17) or
transport (18). Taken together, these examples are
consistent with the indications provided by in silico
analyses which predict the existence of a vast array of
conserved structural features both in selected human
protein coding RNA transcripts (19) and in the human
genome in general (20). From the latter has emerged the
recent small RNAs revolution of functional non-coding
RNAs (20,21).
Interestingly, RNA secondary structures have also been
proposed to play a role in helping the splicing machinery
to distinguish between real exons and pseudoexon
sequences (22). Pseudoexon sequences are loosely deﬁned
as intronic sequences between 50 and 200nt in length that
are ﬂanked by apparently good-to-consensus acceptor and
donor-site signals. These sequences, however, are appar-
ently never recognized by the splicing machinery (23)
although this deﬁnition may contain many exceptions. In
fact, it has recently been proposed that many members of
this class may indeed be used to regulate the relative
abundance of diﬀerent pre-mRNA isoforms by selective
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sequences derived from transposable elements known as
Alu sequences has been recently established as a major
source of ‘real’ coding exonic sequences (25–27).
Nevertheless, estimates regarding pseudoexon sequence
abundance in a typical pre-mRNA molecule has shown
they may outnumber ‘real’ exons by an entire order of
magnitude (23). It is therefore clear that, no matter how
many exceptions to the exclusion rule there may be,
avoiding the insertion of these sequences during the
normal splicing process would be essential for correct
pre-mRNA processing. To achieve this, recent research
has proposed that their exclusion may be achieved by a
combination of factors (23), including an enrichment
within their sequence of inhibitory elements (28,29) or
through the in silico indication that pseudoexons ﬂanking
regions have a distinct tendency to form double-stranded
structures that include the pseudo exon itself (22).
Regarding human diseases, pseudoexon inclusion
events have increasingly been described to occur as a
result of a single-point mutation deep within intronic
regions. In general, these mutations have the eﬀect of
creating either a very good acceptor or donor splice site
followed by the selection of ‘opportunistic’ complemen-
tary sites. A few exceptions that are worth noting have
been described elsewhere where the intronic mutation
aﬀects a regulatory element within the pseudoexon itself
(30–32). For a general review of this topic see Buratti et al.
(33) and Supplemetary Table 1 for an updated list of
pathological pseudoexon inclusion events.
This kind of aberrant insertional events have never had
any coding potential, as they all originate from the chance
occurrence of a triggering mutation. Therefore, no
selection pressure may have been applied during evolution
to regulate their inclusion as far as codon usage/regulatory
sequences are concerned (34,35). Interestingly, one char-
acteristic feature of these pseudoexons is their reduced
length with respect to the normal length spread of exons
which is reported to exist in the human and mouse
genomes (Supplementary Figure S1) (36). This reduced
length, intriguingly similar to the previous estimates of the
‘window’ of naked RNA available for folding after
transcription (37), suggests that intrinsic structural fea-
tures of these RNAs could represent a major determinant
in their ‘exonization’ process. In this work, we have used
representative examples of these pseudoexon inclusion
events to test the importance of RNA secondary structures
in their splicing regulation.
MATERIALS AND METHODS
Plasmids carryingthe ATMpseudoexon wild-type
andmutant sequences
The PY7 plasmid has been described in detail elsewhere
(38). For our purposes, we have inserted two SmaI and
NdeI unique cloning sites at positions 44 and 50,
respectively, in its 111-nt long intron. Both the wild-type
(wt) and gtaa-deleted () ATM sequences were ampliﬁed
from the pATM plasmids used in the original report (32)
and inserted in the SmaI site of PY7 (Figure 1A).
The oligos used for this task were the following:
50-ttgctcaagctcttaactgcaacagtggt-30 (s) and 50-gtcaaacaga
aaattcaaatcccag-30 (as). In order to obtain the ATM
46-48T  mutant a two-step PCR method was used with
the following primers 50-tgagggtacgtatgccctagatg-30 (s) and
50-catctagggcatacgtaccctca-30 (as). From this mutant we
obtained ATM 46-48T 41A  using primers 50-cactctact
gatgaggatacg-30 (s) and 50-cgtatcctcatcagtagagtg-30 (as).
Finally, the primers used to insert the 21–23 substitution
in both the ATM  and ATM 46-48T  mutants were the
following: 50-gtgatataccctcactctac-30 (s) and 50-gtagagtgag
ggtatatcac-30 (as). On the other hand, to obtain the ATM
50-new  mutant we created a unique StuI site by joining
together nucleotides 38–40 (agg) with nucleotides 51–53
(cct). The ATM 50-new  mutation was then introduced
by ligating in this site the 50-gtaggtaagtacgaaggc-30 (s)
and 50-gccttcgtacttacctac-30 (as) oligos. Donor splice-site
scores were calculated according to the NNSplice 0.9
program available at http://www.fruitﬂy.org/seq_tools/
splice.html (39).
Plasmids carrying theCFTR 181111.6kbA`Gwild-type
and mutantsequences
The human genomic fragment ﬂanking the CFTR
pseudoexon region was cloned into the SmaI site in the
modiﬁed PY7 vector (CFTR WT) following ampliﬁcation
with oligos: 50-attggtttttaaaaaaatttttaaattggc-30 (s) and
50-ccatattaaatagaaatgagataatttc-30 (as). In order to
obtain the following mutants the CFTR WT construct
was subjected to two-step PCR method of mutagenesis
using the following primers: 50-atataagttaggtaactaacaa-30
(s) and 50-ttgttagttacctaacttatat-30 (as) for CFTR WT2,
50-atataactaaggttagtaacaa-30 (s) and 50-ttgttactaaccttagtta
tat-30 (as) for CFTR WT3, 50-gatataacttaggtaagtatcaat-30
(s) and 50-attgatacttacctaagttatatc-30 (as) for CFTR WT4,
50-tacttgagatgtaagtaaggt-30 (s) and 50-accttacttacatctca
agta-30 (as) for CFTR MUT, 50-tttattacagcaacaattac-30
(s) and 50-gtaattgttgctgtaataaa-30 (as) for CFTR Del1,
50-agaatcctatgagatgtaag-30 (s) and 50-cttacatctcataggatt
ct-30 (as) for CFTR Del2. Finally, in order to construct
the CFTR Rep mutant a two-step PCR on CFTR MUT
mutant plasmid was performed ﬁrst by using the following
oligos: 50-agaatcctatcatgaagagatgtaag-30 (s) and 50-cttaca
tctcttcatgataggattct-30 (as) and then the resulting mutant
(CFTR Dis) was subjected to the same methodology with
the following primers: 50-tttattacagttcatgcaacaattac-30 (s)
and 50-gtaattgttgcatgaactgtaataaa-30 (as) to make the
CFTR Rep mutant.
In vitro andin Hep3B splicing analysis
Splicing reactions were performed in vitro using capped,
SP-6 transcribed RNAs. Standard reactions were carried
out in a 25ml volume at 308C for 2h. Each reaction
contained 15ml of Nuclear Extract from HeLa cells
(CilBiotech, Mons, Belgium, approx. concentration
10mg/ml), 5ml of 13% (w/v) polyvinyl alcohol, 1mlo f
80mM MgCl2,1ml of 12.5mM ATP, 1ml of 0.5M creatine
phosphate and 1.25ml of 0.4M Hepes-KOH pH=7.3 and
2mlo fin vitro transcribed pre-mRNA at 200mg/ml.
Therefore, the ﬁnal concentrations of the various
4370 Nucleic Acids Research, 2007, Vol. 35, No. 13components in a standard processing reaction were as
follows: 3.2mM MgCl2, 500mM ATP, 20mM creatine
phosphate, 2.7% (w/v) PVA, 20mM Hepes (pH=7.3),
6mg/ml of Hela nuclear extract and 16mg/ml of in vitro
transcribed pre-mRNA. The processed RNAs were
then extracted from the reaction mix using RNAwiz
(Ambion, Inc.) and analysed by RT-PCR using a set of
primers at the beginning of tropomyosin exons 2 and 3,
Figure 1. (A) A schematic diagram of the ATM WT construct. White boxes represent tropomyosin exons 2 and 3 whilst the single line represents the
intron. The arrows indicate the primers used for the RT-PCR analyses of the processed RNA templates. The ATM intronic region is in small letters
whilst pseudoexon sequences are in bold capital letters. The ISPE sequence is underlined and the GTAA nucleotides deleted in the ATM  construct
are in italic. Within the ATM sequence all potential donor and acceptor splice-site sequences together with their scores calculated according to the
NNSplice program are underlined (ND indicates that the splice site is not detected as a viable donor site by the program). It should be noted that
although the ISPE sequence scores very well as a potential donor site it is never used by the splicing machinery. (B) In vitro splicing analysis of the
ATM WT and ATM  RNAs both using radioactive templates (upper panel) and by RT-PCR (lower panel). In order to investigate 50int/50pe donor-
site usage a number of mutants were engineered in the ATM  construct (C shows a schematic diagram). In mutant ATM 46-48T  the 46A and
48G nucleotides were replaced by a T in the ATM  context. This improved 50int donor site was then inactivated by introducing an A for a G
substitution in position 41 (mutant ATM 46-48T 41A ). Cryptic 50int donor-site improvement was also obtained by deleting the G in position 41
(mutant ATM  G41). (D) In vitro splicing analysis of these mutants.
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50-agaccggaattcggatcctctagag-30 (as). In order to insert
the various PY7-based sequences in the eukaryotic
expression vector pcDNA3 the inserts were ampliﬁed
using the following oligos T2F 50-agggtaccagcttgtcgaggagg
acatctcag-30 and T3R 50-cctctagagtcgatcgacctgcagg-30 and
inserted in the KpnI and XbaI sites of pcDNA3.
Liposome-mediated transfections of 3 10
5 human hepa-
tocarcinoma Hep3B cells were performed using DOTAP
Liposomal Transfection Reagent (Alexis Biochemicals)
according to manufacturer instructions. After 18h the
transfectiom medium was replaced with fresh medium and
24h later the cells were washed with PBS and RNA was
puriﬁed using RNAwiz (Ambion). In order to rescue the
splicing of CFTR WT and CFTR WT2 we have also
expressed a variant U1snRNP molecule (C4G U1) that
have been described in a previous work from our lab (40).
DNA bands from EtBr-stained (1mg/ml) agarose gel
(1.5%) were photographed under UV illumination and
acquired using a Kodak EDAS 290 apparatus.
Quantiﬁcation of band intensities in the scanned images
has been performed using the ImageJ software freely
available at http://rsb.info.nih.gov/ij.
RNA secondary structuredetermination
RNA secondary structure determination with the use of
limited V1 RNAse (Ambion), T1 RNAse (Ambion) and S1
nuclease (Fermentas) digestion has been described in detail
elsewhere (5). Brieﬂy, 1mg aliquots of ATM  RNA were
digested in 100ml ﬁnal volume with 0.002 U of RNAse V1,
0.05 U of RNAse T1 and 19 U of S1 nuclease for 10min at
308C. An enzyme-free aliquot was processed together and
used as a control. The cleaved RNAs were retrotranscribed
according to standard protocols using the following anti-
sense primers labelled with
32P-end-labelled oligonucleo-
tide primers: 50-gtcaaacagaaaattcaaatccc-30 for the ATM
pseudoexons and 50-ccatattaaatagaaatgagataatttc-30 for
CFTR pseudoexons. In silico secondary structure predic-
tions were performed using the mFold program (41,42).
RESULTS
Peculiardonor-site usagein theATM pseudoexon
Recently, we have described the inclusion of a 65-nt long
pseudoexon between ATM exons 20 and 21 in a patient
aﬀected by ataxia-telengiectasia (32). The activation event
consisted of a 4nt deletion (GTAA) that occurred within a
high-aﬃnity U1snRNP-binding site that surprisingly was
not a masked 50ss but an internal splicing repressor. This
region was termed ISPE, for Intron-Splicing Processing
Element (32,43). Figure 1A shows the nucleotide sequence
of the pseudoexon (in bold), together with the ISPE
sequence (underlined, the GTAA sequence is in italic) and
its intron ﬂanking regions.
The major peculiarity of this event is represented by the
observation that although the ISPE itself is an excellent
50ss it is never used by the splicing machinery. The reason
for this probably resides in its vicinity to the well-deﬁned
30ss sequence of the ATM pseudoexon (30pe) that
possesses a score of 0.93 according to the NNSplice
program (39). In fact, recent experiments using modiﬁed
U1snRNA molecules binding to consecutive positions
along this pseudoexon have suggested that the U1snRNP
molecule has to be placed 40nt away from the 30ss before
pseudoexon inclusion can be observed (43). Even more
surprisingly, the only donor site (50pe) used in vivo is
represented by a AAGgcaagt non-consensus sequence
(32,43). The GC dinucleotide is a fairly rare donor-site
sequence which accounts for only 0.56% of all donor-site
junctions in humans (44). Moreover, in this speciﬁc
context this choice is made even more peculiar due to
the presence inside the pseudoexon itself of another
reasonable potential donor-site sequence (Figure 1A, the
AGGGTACGA sequence, designated throughout
this work as 50int) in addition to the ISPE itself. In fact,
the 50int site possesses a well above cut-oﬀ score of 0.79 by
the NNSplice program whilst 50pe is not even considered
as a potential donor site by this in silico prediction
program. This diﬀerence in predicted strengths in favour
of 50int is also reﬂected by several other donor-site scoring
methods such as MaxEntScan (ME, MDD, MM and
WMM scores for 50int are 7.38/10.38/7.61/6.10, respec-
tively compared to the scores of 3.24/7.72/4.43/4.95
obtained for 50pe) (45) or Spliceview (46) where 50int has
a predicted score of 81 whereas 50pe is not detected at all.
Setting up an invitro splicing system toanalyse ATM
pseudoexon inclusion
In order to clarify this peculiar mechanism of donor-site
usage it was decided to clone part of this sequence in the
PY7 splicing system for in vitro analysis (Figure 1A). Two
versions of this construct were initially analysed, the
ﬁrst one (ATM WT) containing the wild-type intronic
sequence whilst the second one (ATM ) carrying the 4-nt
(GTAA) deletion that had been previously characterized
to cause pseudoexon activation (32). The transcribed
RNAs from these plasmids were then used in a standard
in vitro splicing assay and analysed both by polyacryla-
mide gel electrophoresis and by RT-PCR in a time-course
analysis (Figure 1B, upper and lower panels, respectively).
As shown in both Figure 1B panels the ATM  RNA
could successfully induce pseudoexon inclusion whilst, as
expected, no pseudoexon inclusion could be detected
during the processing of the ATM WT RNA. It should
also be noted that there is a strong similarity between the
results obtained using the radioactively labelled RNAs
and the RT-PCR products. Subcloning and sequencing of
the RT-PCR reaction in Figure 1B lower panel, lane 4
conﬁrmed that only the 50pe sequence was used in the
pseudoexon inclusion event and failed to detect any use of
the 50int donor site (data not shown). The in vitro data,
therefore, wholly conﬁrmed the previous results obtained
using minigenes and patient’s transcript analyses (32,43).
Investigating donor-site choice in theATM pseudoexon
It was then decided to investigate the eventual activation
of the 50int donor site by introducing two single nucleotide
substitutions in position 46 and 48 (ATM 46-48T 
mutant). As shown in Figure 1C, this had the eﬀect of
improving the predicted NNSplice donor-site score from
4372 Nucleic Acids Research, 2007, Vol. 35, No. 130.79 to 0.99. The ATM 46-48T  mutant was then spliced
in vitro and the results showed that this improvement
caused the almost complete switching from normal
pseudoexon donor-site usage to this internal sequence
(Figure 1D, lane 4). Interestingly, inactivating this
improved cryptic 50gt sequence in the presence of the
46–48 substitutions by mutating it to a 50at sequence
(Figure 1C, ATM 46-48T 41A  mutant) restored splicing
to the ATM  RNA pattern (Figure 1D, lane 6).
However, Figure 1D lane 8 shows that a mutation
(ATM  G41) which strongly improves the predicted
donor-site score in the 50int position from 0.79 to 0.97
(Figure 1C) did not result in preferential usage of this
splice site (compare Figure 1D lane 4 and lane 8). It was
therefore evident that additional factors besides predicted
scores were playing a role in deﬁning donor-site usage
within the ATM pseudoexon. In consideration that RNA
secondary structure represents a potentially very powerful
modiﬁer of splice-site usage it was then decided to
investigate the potential folding of this sequence.
The ATM pseudoexoncan efficiently fold upon
itself to mask splice-site usage
Preliminary in silico analyses obtained using the mFold
program (41,42) suggested that the ATM  pseudoexon
sequence could fold upon itself to form a very compact,
double-stranded structure (Figure 2B). Its existence was
thus tested experimentally by partial RNA digestion using
single and double-strand-speciﬁc RNAses such as V1
(which cleaves double-stranded RNA and stacked RNA
regions), T1 (which cleaves single-stranded guanosines)
and S1 nuclease (which cleaves single-stranded RNA
without sequence speciﬁcity) (Figure 2A). The overall
position of the diﬀerent cleavages shows that the ATM 
pseudoexon sequence does indeed display a structure that
is consistent with the model proposed in Figure 2B.
In addition, it is interesting to note that two particularly
strong RT stops (indicated by arrows in Figure 2A) seem
to enclose the pseudoexon sequence, possibly reﬂecting the
diﬃculty of the RT to travel across a compact structure.
Finally, V1 cleavages can be observed to cluster in the
exactpositionofthe50intcrypticdonorsite,suggestingthat
the double-stranded structure in this region may inhibit
use of this donor site. It is also interesting to note that
a prominent S1 cleavage (black square) is also present
in this region but on the opposite strand to the 50int
splice site, and this may represent a tendency for the U of
the wobble U–G base pair to remain outside the stem
region. Alternatively, the V1 sensitivity of the G in
this wobble U–G base pair may be owing to the fact that
it is stacked in a run of ﬁve purines, making a small internal
bulge in this predicted stem structure. It should be noted,
however, that the overall way in which cleavages are
distributed also provides a general indication regarding
how any approaching molecule will see that particular
RNA region. In this case, the much greater number of
V1 cleavages that occur on both sides of the stem
in correspondence to 50int would suggest that this whole
region predominantly looks like a compact, double-
stranded structure to any approaching molecule.
Taken together, these results allow us to propose
a working model of splice-site usage in this pseudoexon.
In this model, once the repression provided the ISPE
sequence is removed the 50pe sequence is chosen as donor
site because the RNA secondary structure hides the
internal 50int sequence. This is consistent with previous
data which showed that short artiﬁcial hairpins have been
long known to be able to inhibit usage of a donor site
embedded in their stem (47). Moreover, the stem
conﬁguration may also provide a competitive advantage
by approximating the 30pe to the 50pe sequence.
Analysisof therole played by theATM RNA secondary
structure on50int/50pe usage
The importance of internal 50ss availability was then tested
experimentally by engineering a mutant ATM sequence
(ATM 50-new ) that carried a 50ss sequence designed to
remain in an open structure/internal bulge conformation
(Figure 3B). It should be noted that these sequence
changes also abolish the original 50int donor like
sequence according to the NNsplice prediction program
Figure 2. In vitro transcribed ATM  RNA enzymatically digested
with S1 nuclease, T1 and V1 RNases (A: lanes S1, T1 and V1). No
enzyme was added to the RNA in a control reaction mixture
(A: lane C). The RNA substrate on which this analysis was perfomed
consisted of the entire RNA transcript from the ATM  RNA plasmid
( 700nt). By providing an extensive background of ﬂanking RNA
molecule we have aimed to minimize any folding bias that may have
derived from analysing the pseudoexon sequence alone. The cleaved
fragments were detected by performing a RT reaction using a labelled
32P-end labelled antisense oligo and separating them in a denaturing
6% polyacrylamide gel. A sequencing reaction performed with the same
RT primer was run in parallel to the cleavages in order to determine
the cleavage sites (A: lanes G, A, T, C). Squares, circles and triangles
indicate S1, T1 and V1 cleavage sites. Black and white symbols indicate
high and low cleavage intensity, respectively. RT stops are indicated
by arrows. The positions of the 30pe, 50int and 50pe splice sites are
indicated on the right. The observed cleavages were then compared
with the ATM folding predictions by mFold (B).
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not shown). The fact that the ATM 50-new  mutant has a
more open structure also in the mutated 50int donor site is
suggested by the increase of S1 single-strand cleavages
in this region of the ATM 50-new mutant  when
compared with the ATM  mutant (Figures 2B and
3B). The structural probing of this mutant shown in
Figure 3A displays a marked reduction in the number of
V1 cleavages (double-strand speciﬁc) and an increase
in the S1 single-stranded cleavages around the central
bulge region carrying the new donor site. Therefore, with
respect to the structural analysis shown in Figure 2A
for the ATM  mutant, the overall picture of the ATM
50-new  mutant shows a predominantly open conﬁgura-
tion (and thus presumably becomes more accessible for
splicing factors).
In keeping with this, when the activity of this mutant
was tested in vitro (Figure 3C) the results demonstrated
that this time the new internal 50ss are preferentially used
with respect to the 50pe sequence (Figure 3C, compare
lanes 3 and 4). Interestingly, direct sequencing of the
ampliﬁed product has showed that although most frag-
ments ( 75%) derive from the use of the 50-new donor site
whilst the remaining are derived from 50int donor-site
usage (data not shown). This result further highlights the
importance of an ‘open’ structure on donor-site sequence
availability. In addition, because the eﬃciency of pseu-
doexon recognition when transfected in eukaryotic cells
using minigene systems was signiﬁcantly higher than
in vitro (32) the behaviour of this mutant was also tested
following its introduction in pcDNA3 and transfection in
Hep3B cells. Also in this case the ATM 50-new  mutant
was shown to splice predominantly to the internal donor
Figure 3. (A) The structural analysis of the ATM 50new  mutant. Nomenclature of the enzymes and cleavage site intensities are as described in the
legend to Figure 2. (B) A schematic diagram of this mutant. The inserted bases with respect to the ATM  sequence are underlined and in bold. The
in vitro splicing analysis of this 50new  RNA compared with the ATM  RNA is reported in (C). The activation of the novel internal 50ss during
ATM pseudoexon splicing is indicated as a box with vertical lines. The ATM 50new  mutant sequence has also been transferred to the pcDNA3
eukaryotic expression vector and transiently transfected in Hep3B cells (D).
4374 Nucleic Acids Research, 2007, Vol. 35, No. 13sites when transfected in Hep3B cells (Figure 3D, compare
lanes 1 and 2).
Effects ofsecondary structure stability on 50int site
usagein the ATMpseuodexon
The functional importance of RNA secondary structure
was also tested experimentally by performing a more subtle
mutational analysis based on the proposed RNA second-
ary structure of the ATM pseudoexon in Figure 2B.
According to this model, it should be possible to reduce
50int activation in the ATM 46-48T  mutant by
‘tightening’ the upper stem (Figure 4A). In order to do
this, the thymidines in position 21 and 23 were replaced by
cytosine both in the original ATM  context as control
(mutant ATM 21-23C ) and in the ATM 46-48T 
context (mutant ATM 21-23C 46-48T ). The rationale of
this change was to replace the natural UG ‘wobble’ base-
pairings in these positions with two more canonical CG
base pairs. This change, according to secondary structure
predictions, would have the eﬀect of raising the free
energy of the ATM pseudoexon structure from –20.9 to
–26.2kcal/mol (Figure 4A). Figure 4B shows that the
introduction of the 21–23C substitutions had no eﬀect in
donor-site usage of the ATM  context (Figure 4B, lane 4).
However, the same substitutions in the ATM 46-48T 
contextwerecapable ofobtainingthefullinhibitionof50int
usage(Figure4B,lane6).Interestingly, andinkeepingwith
the results obtained by the ATM 46-48T 41A  mutant
(compare Figure 4B, lane 6 with Figure 1D, lane 6), the
inactivation of the 50int donor site also partially restored
splicing to the 50pe natural donor sequence.
The inhibitory behaviour of the 21-23C substitutions in
the 46-48T context with regards to 50int usage are also
clearly visible when the same mutants are cloned in
pcDNA3 and transfected in Hep3B cells (Figure 4C,
compare lanes 2 and 3), although a marked reduction in
splicing eﬃciency was also observed in this case.
Donor-site usagein theCFTR 181111.6kbA`G
pseudoexon
Splice-site mutation 1811+1.6kbA4G occurs in intron
11 of the CFTR gene and creates a novel 50 splice site. This
mutation results in the inclusion of a cryptic 49bp exon in
the ﬁnal mature mRNA (48). As shown in Figure 5A, an
interesting feature of this pseudoexon is represented by the
fact that near to the newly created donor site (50pe) there is
a second, not optimal, but viable donor-site sequence
(/guuacu, 50ss) detected by the NNSplice prediction
program. This was an interesting ﬁnding, as other likely
donor-site sequences had already been identiﬁed in the
original study (48). Indeed, an interesting feature of this
CFTR sequence is represented by its containing several
downstrean donor-like sequences after the activating
mutation (/guaa/guaag/guuacu). However, at the time
no indication could be obtained that any of these
additional donor-site sequences besides the one created
by the A4G mutation were ever used in normal CFTR
pre-mRNA splicing (48). Using our PY7 in vitro system we
Figure 4. (A) The two T4C substitutions in positions 21 and 23 that have the eﬀect of tightening the upper stem by replacing the two ‘wobble’
UG base pairs with two CG bonds. These two substitutions were introduced both in the ATM  context (mutant ATM 21-23C ) and in the ATM
46-48T  (mutant ATM 46-48T 21-23C ) context. The in vitro and in Hep3B splicing analyses of these mutants is shown in (B) and (C).
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the CFTR WT sequence that lacks the A4G substitution
does not give rise to any pseudoexon insertion event
originating from the 50ss natural sequence (lane 2).
In addition, when the A4G substitution was inserted in
the sequence (mutant CFTR MUT) only one pseudoexon
inclusion event could be observed (Figure 5B, lane 4)
that originated from this newly created 50pe donor
site as determined by sequencing of the upper band
(data not shown).
As in the ATM pseudoexon example, in silico analysis
of this sequence (Figure 5D) suggested that avoidance of
50ss usage in normal splicing could be ascribed to a
particular folding of this RNA. An alternative explanation
for the lack of 50ss usage may also reside in the peculiar
arrangement of the CFTR sequence (see earlier) where
Figure 5. (A) The sequence of the CFTR intronic region inserted in the SmaI site of PY7 that contains the A4G mutation responsible for creating a
high score donor site (50pe) (highlighted in bold). The positions and scores of the acceptor (30pe) and additional donor splice site (50ss) that occur
within this sequence are also shown. (B) In vitro splicing reaction of two transcripts, one that did not contain the A to G substitution (CFTR WT)
and the other carrying the A to G pseudoexon-creating mutation (CFTR MUT). (C) The structural analysis of CFTR MUT using limited RNAse
digestion with the S1, V1 and T1 enzymes (nomenclature of the cleavages and of the enzymes used is as described in Figure 2 legend) and the in silico
predicted structure on which the individual cleavages have been reported (D).
4376 Nucleic Acids Research, 2007, Vol. 35, No. 13tandem donor-like sequences (/guaag/guuacu) are closely
grouped together, an event that may lead to splicing
inhibition probably at the level of the A and B complexes
due to sterical hindrance of closely binding U1snRNP
molecules, as proposed by Nelson and Green in previous
studies (49). In this CFTR system, however, this
possibility is unlikely as U1snRNP cannot be detected as
binding to this position in the normal CFTR WT context,
at least as determined by super-shift analysis using a anti-
U1A monoclonal antibody (data not shown).
Therefore, in order to conﬁrm the structural hypothesis
we ﬁrst performed RNAse digestion analysis on the PY7
MUT transcript. As shown in Figure 5C, the cleavages
were consistent with the secondary structure depicted in
Figure 5D and in particular the inactive 50ss donor site
appears to be embedded in a tightly folded structure, as
highlighted by the two strong V1 cleavages that immedi-
ately ﬂank the two T1 cuts in correspondence to the GG
nucleotides. Although this would seemingly make an
energetically very unfavourable, 2nt loop conﬁguration,
it should be noted that in order to cleave the V1 RNAse
does not necessarily require a bonded interaction but only
a suﬃciently close distance between two nucleotides.
On the other hand, the newly created 50pe (Figure 5D) is
localized in the apparently more open region joining two
stem-loop structures.
Investigating repression of 50ss usagein the
CFTR WT context
In order to better understand the molecular mechanisms
that repress 50ss usage in the CFTR WT transcript it was
then decided to test the importance of predicted donor-site
strengths on CFTR WT pseudoexon inclusion eﬃciency.
As shown in Figure 6A, three mutants (WT2, WT3 and
WT4) were created in which we substantially improved
the predicted donor-site scores (0.98, 1.00 and 1.00,
respectively) according to NNSplice without changing
the structure and base-composition of the lower stem. The
improvement in predicted strengths for these mutants was
very evident using also other in silico prediction programs
such as MaxEnt scan that focus only on the 9nt consensus
stretch itself. In this case, the predicted 50ss donor-site
strengths according to the ME, MDD, MM and WMM
scoring models were 1.25/6.68/2.34/3.92 for WT, 6.43/
10.08/5.09/7.20 for WT2, 8.54/13.58/7.21/7.76 for WT3
and 9.66/13.68/9.96/11.04 for WT4. In vitro splicing
analysis of these mutants (Figure 6B, compare lanes 2,
4, 6 and 8) clearly showed that only WT3 and WT4 were
capable of promoting pseudoexon inclusion from their
mutated 50ss sequences. This diﬀerence between the
splicing behaviour of the WT2 and WT3 mutants
(Figure 6B, compare lanes 4 and 6) prompted us to
focus on the importance of the +5 position.
Therefore, we decided to improve the CFTR
WT-U1snRNP matching region in this position by
co-transfecting a modiﬁed U1snRNP molecule (C4G
U1) that has been previously used to recover splicing from
a +5G4C mutated donor site in exon 3 of the NF-1 gene
(see Figure 6C and D, lanes 1 and 2) (40). The results of
this experiment showed that CFTR WT could not display
pseudoexon inclusion even when cotransfected with the
C4G U1 (Figure 6D, lanes 3 and 4) whilst only a very
small amount of pseudoexon inclusion could be observed
when the CFTR WT2 mutant was cotransfected with this
C4G U1 (Figure 6D, lane 6). Interestingly, addition of
the C4G U1 to the CFTR WT 50ss donor site gives a
complementarity pattern that was identical to the one
obtained by the CFTR WT3 mutant with wild-type U1
molecule (Figure 6C, compare boxes 2 and 3). However, in
the ﬁrst case no pseudoexon inclusion was observed
(Figure 6D, lane 4) whilst the CFTR WT3 mutant could
naturally promote inclusion (Figure 6B, lane 6). This
ﬁnding suggests that the critical importance of the +5
position might be unrelated to U1snRNP binding and the
most likely possibility is represented by the interaction
with U6snRNP, that would remain impaired in the CFTR
WT+ C4G U1 system whilst it would be unimpeded in
the CFTR WT3 mutant. This hypothesis cannot, however,
explain the recovery of CFTR WT2 pseudoexon recogni-
tion (although at very low levels) in the presence of C4G
U1. However, in this case it may well be found that the
very extended complementarity between the CFTR WT2
sequence and the C4G U1 (Figure 6C, lower right
schematic diagram) may still promote donor-site usage.
It should also be noted that the level of splicing recovery is
considerably less than the one obtained for the NF-1 exon
3 donor site in the presence of C4G U1 (Figure 6D,
compare lanes 2 and 6) although there is an even greater
complementarity between CFTR WT2 with the C4GU 1
sequence (Figure 6C, compare boxes 1 and 4). Taken
together, all these diﬀerences suggest that the secondary
structure may represent an additional constraint to the use
of this splicing system.
Further investigating the relationship between second-
ary structure and this 50ss donor-site usage would none-
theless represent a very diﬃcult task as modiﬁcations
introduced to change the folding of the stem structure
involved would also aﬀect donor-site strength and
possibly activate the nearby donor consensus elements.
Therefore, it was decided to focus our attention on the
major structural element of this particular sequence.
Importance ofRNA secondary structure on CFTR
181111.6kbA`G inclusion
Indeed, disruption of the major structural features of this
RNA region should aﬀect the eﬃciency of CFTR
pseudoexon inclusion. Thus, we began testing this by
selectively deleting the supporting lower stem in either of
the two strands (mutants CFTR Del1 and Del2, see
Figure 7A for a schematic diagram). In parallel, in order
to test the importance of sequence conservation within the
pseudoexon the structure was either ‘disrupted’ and then
‘repaired’ by engineering mutants CFTR Dis and CFTR
Rep (see Figure 7C for a schematic diagram). These
mutants were then tested either in vitro or following
transfection in Hep3B cells for ability to recognize the
pseudoexon (Figure 7B and D, respectively).
For the ﬁrst set of constructs, the results demonstrate
that pseudoexon inclusion in vitro is reduced from 50%
inclusion in the CFTR MUT construct to 22% in the Del1
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strikingly, pseudoexon inclusion is almost completely
abolished in the CFTR Del1 mutant when transfected in
Hep3B cells (Figure 7B, right panel, lane 2). It should also
be noted that the Del1 deletion changes only slightly the
predicted strength of the 30splice site of the CFTR
pseudoexon (from a score of 0.96 to 0.91 according to
the NNSplice program), ruling out the possibility that
this deletion may have simply aﬀected the quality of
this site. On the other hand, no eﬀect on splicing
eﬃciency with respect to the CFTR MUT could be
observed for the Del2 mutant in transfected Hep3B cells
(Figure 7B, right panel, lane 3) whilst a small increase
(to 68% inclusion) was observed in vitro (Figure 7B,
left panel, lane 6).
For the second set of constructs it was observed that
the pseudoexon in the CFTR Dis mutant was recognized
with reduced eﬃency both in vitro and in Hep3B
Figure 6. (A) A schematic diagram of the three CFTR WT mutants (WT2, WT3 and WT4). The stem-conservative mutations introduced in these
constructs are highlighted in gray and the relative predicted strengths of the resulting 50ss sequences are also indicated. The splicing pattern displayed
by these mutants in vitro is shown in (B). In (C) there is a schematic diagram of the predicted base-pairing between the 50 end of wild-type U1snRNP
(WT U1) and of the mutant U1snRNP (C4G U1) with the three diﬀerent constructs tested: the NF-1 exon 3, the CFTR WT and CFTR WT2 50ss
sequences. (D) The eﬀects of overexpressing the mutant C4G U1 in the presence of each of the three constructs in Hep3B cells. It should be noted
that U1 rescue is more eﬃcient in other cell types such as HeLa cells.
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In fact, pseudoexon inclusion in the CFTR Dis mutant fell
to 30% in the in vitro splicing assay (from a 50% starting
value of CFTR MUT in vitro) and to 64% inclusion in
Hep3B cells (from a starting value of 93% inclusion for
CFTR MUT in Hep3B cells). On the other hand, in
keeping with the structural predictions, the CFTR Rep
mutant fully recovered splicing eﬃciency with respect to
the CFTR MUT construct (Figure 7D, left panel lane 6
and right panel lane 3). These results were thus in keeping
with the proposed regulatory role of RNA structure on
CFTR pseudoexon inclusion. Furthermore, they demon-
strated that conservation of the primary nucleotide
sequences was not required.
Nonetheless, on the basis of secondary structure
considerations alone (Figure 7A) we also would have
expected the Del1 and Del2 mutants to have similar eﬀects
on splicing eﬃciency. It was therefore of interest to check
whether the splicing changes detected could be correlated
with unforeseeable diﬀerential structural rearrangements
introduced by these two mutations.
Structural analysis ofthe CFTR Del1-Del2 mutants
The results of the structural analysis performed on the
Del1 mutant (Figure 8B) showed that this RNA displayed
a markedly diﬀerent RNAse proﬁle with respect to the
CFTR MUT proﬁle (Figure 8A) and CFTR Del2
(Figure 8C). In particular, with the exception of the 50ss
region, there is very little conservation in cleavage pattern
proﬁles between the CFTR Del1 mutant and the CFTR
MUT, CFTR Del2 mutants. As shown in the schematic
Figure 7. (A) A schematic diagram of the two deletion mutants (CFTR Del1 and CFTR Del2) inserted in the PY7 system starting from the CFTR
MUT plasmid. The splicing pattern displayed by these mutants either in vitro (left panel) or when transfected in Hep3B cells (right panel) is shown in
(B). (C) The schematic diagram of an additional set of CFTR mutants (CFTR Dis and CFTR Rep) that were subjected to in vitro splicing (D: left
panel) and transfected in Hep3B cells (D, right panel).
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predicted Del1 structure (Figure 8E) that includes the 50pe,
50ss, and 30pe in a stem conﬁguration, presumably making
them less available to the splicing machinery. On the other
hand, the cleavage pattern obtained for the Del2 mutant is
very similar to that obtained for the MUT sequence
(compare Figure 8A and C), up to the conservation of
several RT stops indicated by arrows. Finally, in support
of the structural changes detected in the Del1/Del2
mutants it has to be noted that the cleavages in
correspondence to the 50ss position are mostly conserved
in all three structures (Figure 8A, B and C, 50ss region),
demonstrating that the diﬀerences in cleavage eﬃciencies
for the diﬀerent mutants do not represent an artifactual
occurrence owing to diﬀerent RNAse activities/eﬃciencies
in the three analyses.
Therefore, the result of this analysis were also consistent
with a proposed regulatory role of the major stem-loop
element in CFTR pseudoexon inclusion. In addition,
these results also highlight the ‘unpredictability’ of
mutations aimed to modify RNA structural elements.
In fact, based just on the 2D structural predictions the
Del1 and Del2 mutations should have resulted in similar
eﬀects. The fact that limited RNAse digestion analysis
showed this not to be the case underscores the need for
direct experimental testing of secondary structures when-
ever evaluating the potential eﬀects of introduced
mutations.
DISCUSSION
Pre-mRNA secondary structure is increasingly recognized
as a general modiﬁer of splicing (1). However, evaluating
its inﬂuence on the processing of individual exons is often
a very diﬃcult task and any research on RNA structures
Figure 8. (A, B and C) The enzymatic structure determination proﬁles of the CFTR MUT, CFTR Del1 and CFTR Del2 RNAs using RNAse
digestion with the S1, V1 and T1 enzymes. Nomenclature of the cleavages and of the enzymes used is as described in Figure 2 legend. (D, E and F)
The predicted RNA secondary structure of each RNA together with the corresponding cleavages observed in each probing assay. The positions of
the acceptor (30pe), pseudoexon donor (50pe) and additional (50ss) donor sites are indicated.
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out additional sources of bias. These include conservation
of coding potential (35,50–52), the vast array of positive
and negative cis-acting sequences that are now known to
be present in most coding sequences (33,34,53), and that
the RNA structure itself can be heavily inﬂuenced by
RNA–protein interactions (54). Indeed, to this date very
few examples exist regarding the existence of splicing-
regulatory secondary structures residing entirely within
exonic coding regions (5,6). It is diﬃcult to assess if this
scant representation of secondary structure is a feature of
exons or the fact that they have never been extensively
searched for, particularly in view of the laborious task of
conﬁrming unreliable computer predictions in naked
RNA and the almost impossibility up to now of probing
structure in vivo. Hopefully, the recent increase in
sequencing data from many diﬀerent organisms coupled
with ever more reﬁned folding algorithms and new
technologies for gene expression visualization will allow
researchers to identify additional likely examples of
regulatory structural elements within mRNA molecules
(19). It is also very possible that the often highly intricate
network of regulatory processes embedded in exons/
introns (33,55–58) and the need for the processed
mRNA molecule to be translated, have all contributed
to keep the 50ss and 30ss of real exons in regions of limited
RNA structure.
Many of these limitations, of course, do not apply to
intronic or non-coding sequences. Indeed, conserved stem-
loop regions within introns have been recently shown to
play a role in the pre-mRNA splicing processes of human
SMN exon 7 (59), human COL2A1 exon 2 (60), in the
highly conserved insect homeothorax gene (61) and in the
yeast YRA1 gene (62). In addition, the structure-forming
ability of introns has been very useful to explain a whole
range of splicing phenomena that would otherwise be
diﬃcult to explain if the pre-mRNA molecule was
considered as existing in a predominantly linear form
(11–13,63).
In this work we have studied the importance of RNA
secondary structure in pseudoexon inclusion events that
are involved in human disease. These pseudoexons
originate from the inclusion of apparently random
intronic sequences following the introduction of an
activating mutation, in general the creation of a novel
acceptor or donor splice site although new observations
also include modiﬁcations within splicing regulatory
elements (see Supplementary Table 1 for a comprehensive
list of these events). Our investigation of an event that
concerns the deletion of a splicing suppressing element in
the ATM gene (32) or of a splice-site creation event in the
CFTR gene (48) has shown that in both cases RNA
secondary structure plays a major role on donor-site usage
and splicing eﬃciency.
Moreover, our results concerning the reasons that
underlie the lack of use of an apparently viable 50ss
splice site in the CFTR genomic sequence has suggested
that the RNA secondary structure may play a role of
inhibiting post U1snRNP interactions, such as that with
U6snRNP, by providing an additional inhibitory inﬂuence
on the suboptimal +5 position. In this respect, therefore,
our observations conﬁrm previous suggestions that RNA
secondary structures may have a general inhibitory eﬀect
on pseudoexon sequences (22). In fact, the presence of
potentially fully functional splice-site sequences within the
intronic sequences of most genes clearly shows that at least
some of these sequences would not really be expected to
wait for an activating mutation in order to be partially
included in the ﬁnal mRNA molecule. However, if these
splice-site sequences ﬁnd themselves bracketing sequences
containing binding sites for splicing inhibitor molecules
or, like in our cases, embedded into unfavourable RNA
structures, then an explanation can be oﬀered regarding
why additional requirements have to be satisﬁed in
order to obtain their ‘upgrade’ to exon status (for
example, their presence in an ‘open’ structural conﬁgura-
tion). The diﬃculty in evaluating these events on the basis
of the primary sequence alone can also be appreciated
from the performance of 50ss scoring programs used in this
work. In fact, beside the MaxEnt Scan evaluation
methods that consider the MAG|GURAGU (M is A or
C; R is purine) consensus sequence even methods such as
NNsplice that consider in their evaluation sequences
beyond the strict consensus fail to accurately predict the
exact donor-site usage observed in our experimental
systems. Our results will hopefully provide further
information to facilitate the ﬁne tuning of these splice-
site prediction algorithms.
It should be noted, however, that RNA secondary
structure may not represent the only determining factor in
the ATM or CFTR pseudoexons, as highlighted by some
of our experiments (i.e. Figure 4C) where the structure-
aﬀecting mutations also cause a drop in overall splicing
eﬃciency of the pseudoexon. These results raise the
possibility that splicing controlling elements may also be
aﬀected by these changes. In the future, it will be
interesting to study in selected examples the potential
interplay between RNA structural features and potential
enhancer and silencer splicing controlling regions present
in the pseudoexon of the type already demonstrated in the
ﬁbronectin EDA exon (5). Indeed, the role played by
splicing factors in pseudoexon inclusion is a promising
issue that remains to be fully investigated in the splicing
ﬁeld. In fact, in at least a minority of cases pseudoexon
inclusion has been strongly correlated with creation of
splicing regulatory enhancer elements (30–32). A similar
situation may be present for nucleotide variations that
remove the binding site for splicing inhibitory factors (32).
Nonetheless, our work suggests that taking into account
structural features may represent a useful strategy to
understand the functional mechanisms that underlie the
activation of pseudoexon sequences in other genes causing
human genetic diseases. This may be important also for
attempting novel molecular therapy approaches to modify
the regulation of pseudoexon inclusion events and for
reﬁning computer algorithms for the prediction of the
splicing eﬀect of any genomic variation. In fact, from a
molecular therapy point of view the mapping of pseu-
doexon RNA secondary structures may provide useful
indications regarding the development of inhibitory
molecules such as antisense nucleotide that have already
Nucleic Acids Research, 2007, Vol. 35, No. 13 4381been suggested to possess increased working eﬃciency
when targeted against open structural regions (64).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We wish to thank C.W. Smith for his kind gift of the PY7
plasmid. This work was supported by Telethon Onlus
Foundation (Italy) (grant no. GGP02453 and
GGP06147), FIRB (RBNE01W9PM) and by a
European community grant (EURASNET- LSHG-CT-
2005-518238). Funding to pay the Open Access publica-
tion charges for this article was provided by ICGEB.
Conﬂict of interest statement. None declared.
REFERENCES
1. Buratti,E. and Baralle,F.E. (2004) Inﬂuence of RNA secondary
structure on the pre-mRNA splicing process. Mol. Cell. Biol., 24,
10505–10514.
2. Donahue,C.P., Muratore,C., Wu,J.Y., Kosik,K.S. and Wolfe,M.S.
(2006) Stabilization of the Tau Exon 10 stem loop alters pre-mRNA
splicing. J. Biol. Chem., 281, 23302–23306.
3. Singh,N.N., Singh,R.N. and Androphy,E.J. (2007) Modulating role
of RNA structure in alternative splicing of a critical exon in the
spinal muscular atrophy genes. Nucleic Acids Res., 35, 371–389.
4. Chen,Y. and Stephan,W. (2003) Compensatory evolution of a
precursor messenger RNA secondary structure in the Drosophila
melanogaster Adh gene. Proc. Natl Acad. Sci. USA, 100,
11499–11504.
5. Buratti,E., Muro,A.F., Giombi,M., Gherbassi,D., Iaconcig,A. and
Baralle,F.E. (2004) RNA folding aﬀects the recruitment of SR
proteins by mouse and human polypurinic enhancer elements in the
ﬁbronectin EDA exon. Mol. Cell. Biol., 24, 1387–1400.
6. Higashide,S., Morikawa,K., Okumura,M., Kondo,S., Ogata,M.,
Murakami,T., Yamashita,A., Kanemoto,S., Manabe,T. et al. (2004)
Identiﬁcation of regulatory cis-acting elements for alternative
splicing of presenilin 2 exon 5 under hypoxic stress conditions.
J. Neurochem., 91, 1191–1198.
7. Spingola,M., Grate,L., Haussler,D. and Ares,M. (1999)
Genome-wide bioinformatic and molecular analysis of introns
in Saccharomyces cerevisiae. RNA, 5, 221–234.
8. Howe,K.J. and Ares,M. (1997) Intron self-complementarity enforces
exon inclusion in a yeast pre-mRNA. Proc. Natl Acad. Sci. USA,
94, 12467–12472.
9. Miriami,E., Margalit,H. and Sperling,R. (2003) Conserved sequence
elements associated with exon skipping. Nucleic Acids Res., 31,
1974–1983.
10. Lian,Y. and Garner,H.R. (2005) Evidence for the regulation of
alternative splicing via complementary DNA sequence repeats.
Bioinformatics, 21, 1358–1364.
11. Baraniak,A.P., Lasda,E.L., Wagner,E.J. and Garcia-Blanco,M.A.
(2003) A stem structure in ﬁbroblast growth factor receptor 2
transcripts mediates cell-type-speciﬁc splicing by approximating
intronic control elements. Mol. Cell. Biol., 23, 9327–9337.
12. Graveley,B.R. (2005) Mutually exclusive splicing of the insect
Dscam pre-mRNA directed by competing intronic RNA secondary
structures. Cell, 123, 65–73.
13. Kreahling,J.M. and Graveley,B.R. (2005) The iStem, a long-range
RNA secondary structure element required for eﬃcient exon
inclusion in the Drosophila Dscam pre-mRNA. Mol. Cell. Biol., 25,
10251–10260.
14. Smith,C.W. (2005) Alternative splicing–when two’s a crowd. Cell,
123, 1–3.
15. Dixon,R.J., Eperon,I.C. and Samani,N.J. (2007) Complementary
intron sequence motifs associated with human exon repetition:
a role for intragenic, inter-transcript interactions in gene expression.
Bioinformatics, 23, 150–155.
16. Chamary,J.V. and Hurst,L.D. (2005) Evidence for selection on
synonymous mutations aﬀecting stability of mRNA secondary
structure in mammals. Genome Biol., 6, R75.
17. Baird,S.D., Turcotte,M., Korneluk,R.G. and Holcik,M. (2006)
Searching for IRES. RNA, 12, 1755–1785.
18. Li,Y., Bor,Y.C., Misawa,Y., Xue,Y., Rekosh,D. and
Hammarskjold,M.L. (2006) An intron with a constitutive transport
element is retained in a Tap messenger RNA. Nature, 443, 234–237.
19. Meyer,I.M. and Miklos,I. (2005) Statistical evidence for conserved,
local secondary structure in the coding regions of eukaryotic
mRNAs and pre-mRNAs. Nucleic Acids Res., 33, 6338–6348.
20. Washietl,S., Hofacker,I.L., Lukasser,M., Huttenhofer,A. and
Stadler,P.F. (2005) Mapping of conserved RNA secondary
structures predicts thousands of functional noncoding RNAs in the
human genome. Nat. Biotechnol., 23, 1383–1390.
21. Mendes Soares,L.M. and Valcarcel,J. (2006) The expanding
transcriptome: the genome as the ‘Book of Sand’. EMBO J., 25,
923–931.
22. Zhang,X.H., Leslie,C.S. and Chasin,L.A. (2005) Dichotomous
splicing signals in exon ﬂanks. Genome Res., 15, 768–779.
23. Sun,H. and Chasin,L.A. (2000) Multiple splicing defects in an
intronic false exon. Mol. Cell. Biol., 20, 6414–6425.
24. Grellscheid,S.N. and Smith,C.W. (2006) An apparent
Pseudo-Exon acts both as an alternative exon that leads
to nonsense-mediated decay and as a zero-length exon.
Mol. Cell. Biol., 26, 2237–2246.
25. Sorek,R., Lev-Maor,G., Reznik,M., Dagan,T., Belinky,F.,
Graur,D. and Ast,G. (2004) Minimal conditions for exonization of
intronic sequences: 50 splice site formation in alu exons. Mol. Cell,
14, 221–231.
26. Krull,M., Brosius,J. and Schmitz,J. (2005) Alu-SINE
exonization: en route to protein-coding function. Mol. Biol. Evol.,
22, 1702–1711.
27. Lei,H., Day,I.N. and Vorechovsky,I. (2005) Exonization of AluYa5
in the human ACE gene requires mutations in both 30 and 50 splice
sites and is facilitated by a conserved splicing enhancer.
Nucleic Acids Res., 33, 3897–3906.
28. Zhang,X.H. and Chasin,L.A. (2004) Computational deﬁnition of
sequence motifs governing constitutive exon splicing. Genes Dev.,
18, 1241–1250.
29. Sironi,M., Menozzi,G., Riva,L., Cagliani,R., Comi,G.P.,
Bresolin,N., Giorda,R. and Pozzoli,U. (2004) Silencer elements as
possible inhibitors of pseudoexon splicing. Nucleic Acids Res., 32,
1783–1791.
30. Ishii,S., Nakao,S., Minamikawa-Tachino,R., Desnick,R.J. and
Fan,J.Q. (2002) Alternative splicing in the alpha-galactosidase
A gene: increased exon inclusion results in the Fabry cardiac
phenotype. Am. J. Hum. Genet., 70, 994–1002.
31. King,K., Flinter,F.A., Nihalani,V. and Green,P.M. (2002) Unusual
deep intronic mutations in the COL4A5 gene cause X linked Alport
syndrome. Hum. Genet., 111, 548–554.
32. Pagani,F., Buratti,E., Stuani,C., Bendix,R., Dork,T. and
Baralle,F.E. (2002) A new type of mutation causes a splicing defect
in ATM. Nat. Genet., 30, 426–429.
33. Buratti,E., Baralle,M. and Baralle,F.E. (2006) Defective splicing,
disease and therapy: searching for master checkpoints in exon
deﬁnition. Nucleic Acids Res., 34, 3494–3510.
34. Pagani,F. and Baralle,F.E. (2004) Genomic variants in exons and
introns: identifying the splicing spoilers. Nat. Rev. Genet., 5,
389–396.
35. Chamary,J.V., Parmley,J.L. and Hurst,L.D. (2006) Hearing
silence: non-neutral evolution at synonymous sites in mammals.
Nat. Rev. Genet., 7, 98–108.
36. Sakharkar,M.K., Perumal,B.S., Sakharkar,K.R. and Kangueane,P.
(2005) An analysis on gene architecture in human and mouse
genomes. In Silico Biol., 5, 347–365.
37. Eperon,L.P., Graham,I.R., Griﬃths,A.D. and Eperon,I.C. (1988)
Eﬀects of RNA secondary structure on alternative splicing of pre-
mRNA: is folding limited to a region behind the transcribing RNA
polymerase? Cell, 54, 393–401.
4382 Nucleic Acids Research, 2007, Vol. 35, No. 1338. Deirdre,A., Scadden,J. and Smith,C.W. (1995) Interactions
between the terminal bases of mammalian introns are retained
in inosine-containing pre-mRNAs. EMBO J., 14, 3236–3246.
39. Reese,M.G., Eeckman,F.H., Kulp,D. and Haussler,D. (1997)
Improved splice site detection in Genie. J. Comput. Biol., 4,
311–323.
40. Baralle,M., Baralle,D., De Conti,L., Mattocks,C., Whittaker,J.,
Knezevich,A., Ffrench-Constant,C. and Baralle,F.E. (2003)
Identiﬁcation of a mutation that perturbs NF1, a gene splicing
using genomic DNA samples and a minigene assay. J. Med. Genet.,
40, 220–222.
41. Mathews,D.H., Sabina,J., Zuker,M. and Turner,D.H. (1999)
Expanded sequence dependence of thermodynamic parameters
improves prediction of RNA secondary structure. J. Mol. Biol., 288,
911–940.
42. Zuker,M. (2003) Mfold web server for nucleic acid folding and
hybridization prediction. Nucleic Acids Res., 31, 3406–3415.
43. Lewandowska,M.A., Stuani,C., Parvizpur,A., Baralle,F.E. and
Pagani,F. (2005) Functional studies on the ATM intronic splicing
processing element. Nucleic Acids Res., 33, 4007–4015.
44. Burset,M., Seledtsov,I.A. and Solovyev,V.V. (2001) SpliceDB:
database of canonical and non-canonical mammalian splice sites.
Nucleic Acids Res., 29, 255–259.
45. Yeo,G. and Burge,C.B. (2004) Maximum entropy modeling of short
sequence motifs with applications to RNA splicing signals.
J. Comput. Biol., 11, 377–394.
46. Rogozin,I.B. and Milanesi,L. (1997) Analysis of donor splice sites in
diﬀerent eukaryotic organisms. J. Mol. Evol., 45, 50–59.
47. Goguel,V., Wang,Y. and Rosbash,M. (1993) Short artiﬁcial hair-
pins sequester splicing signals and inhibit yeast pre-mRNA splicing.
Mol. Cell. Biol., 13, 6841–6848.
48. Chillon,M., Dork,T., Casals,T., Gimenez,J., Fonknechten,N.,
Will,K., Ramos,D., Nunes,V. and Estivill,X. (1995) A novel donor
splice site in intron 11 of the CFTR gene, created by mutation
1811+1.6kbA–4G, produces a new exon: high frequency in
Spanish cystic ﬁbrosis chromosomes and association with severe
phenotype. Am. J. Hum. Genet., 56, 623–629.
49. Nelson,K.K. and Green,M.R. (1988) Splice site selection and
ribonucleoprotein complex assembly during in vitro pre-mRNA
splicing. Genes Dev., 2, 319–329.
50. Pagani,F., Raponi,M. and Baralle,F.E. (2005) Synonymous muta-
tions in CFTR exon 12 aﬀect splicing and are not neutral in
evolution. Proc. Natl Acad. Sci. USA, 102, 6368–6372.
51. Xing,Y. and Lee,C. (2006) Alternative splicing and RNA selection
pressure–evolutionary consequences for eukaryotic genomes.
Nat. Rev. Genet., 7, 499–509.
52. Parmley,J.L., Chamary,J.V. and Hurst,L.D. (2006) Evidence for
purifying selection against synonymous mutations in mammalian
exonic splicing enhancers. Mol. Biol. Evol., 23, 301–309.
53. Cartegni,L., Chew,S.L. and Krainer,A.R. (2002) Listening to silence
and understanding nonsense: exonic mutations that aﬀect splicing.
Nat. Rev. Genet., 3, 285–298.
54. Schroeder,R., Barta,A. and Semrad,K. (2004) Strategies for RNA
folding and assembly. Nat. Rev. Mol. Cell. Biol., 5, 908–919.
55. Matlin,A.J., Clark,F. and Smith,C.W. (2005) Understanding
alternative splicing: towards a cellular code. Nat. Rev. Mol.
Cell. Biol., 6, 386–398.
56. Singh,R. and Valcarcel,J. (2005) Building speciﬁcity with
nonspeciﬁc RNA-binding proteins. Nat. Struct. Mol. Biol., 12,
645–653.
57. Black,D.L. (2003) Mechanisms of alternative pre-messenger RNA
splicing. Annu. Rev. Biochem., 72, 291–336.
58. Caceres,J.F. and Kornblihtt,A.R. (2002) Alternative splicing:
multiple control mechanisms and involvement in human disease.
Trends Genet., 18, 186–193.
59. Miyaso,H., Okumura,M., Kondo,S., Higashide,S., Miyajima,H. and
Imaizumi,K. (2003) An intronic splicing enhancer element in
survival motor neuron (SMN) pre-mRNA. J. Biol. Chem., 278,
15825–15831.
60. McAlinden,A., Havlioglu,N., Liang,L., Davies,S.R. and Sandell,L.J.
(2005) Alternative splicing of type II procollagen exon 2 is regulated
by the combination of a weak 50 splice site and an adjacent intronic
stem-loop cis element. J. Biol. Chem., 280, 32700–32711.
61. Glazov,E.A., Pheasant,M., McGraw,E.A., Bejerano,G. and
Mattick,J.S. (2005) Ultraconserved elements in insect
genomes: a highly conserved intronic sequence implicated
in the control of homothorax mRNA splicing. Genome Res., 15,
800–808.
62. Preker,P.J. and Guthrie,C. (2006) Autoregulation of the mRNA
export factor Yra1p requires ineﬃcient splicing of its pre-mRNA.
RNA, 12, 994–1006.
63. Schwarze,U., Hata,R., McKusick,V.A., Shinkai,H., Hoyme,H.E.,
Pyeritz,R.E. and Byers,P.H. (2004) Rare autosomal recessive
cardiac valvular form of Ehlers-Danlos syndrome results
from mutations in the COL1A2 gene that activate the
nonsense-mediated RNA decay pathway. Am. J. Hum. Genet., 74,
917–930.
64. Aartsma-Rus,A., De Winter,C.L., Janson,A.A., Kaman,W.E.,
Van Ommen,G.J., Den Dunnen,J.T. and Van Deutekom,J.C. (2005)
Functional analysis of 114 exon-internal AONs for targeted DMD
exon skipping: indication for steric hindrance of SR protein binding
sites. Oligonucleotides, 15, 284–297.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4383